Introduction: The manuscript analyzes the frequency of asymptomatic hyperuricemia in association with disturbance of glucose and lipid metabolism, inflammatory process, and kidney changes in patients with essential arterial hypertension (EAH) and concomitant diabetes mellitus type 2 (DM2).
Aim: To determine the frequency of asymptomatic hyperuricemia in patients with EAH and concomitant DM2 and their effects on the main indicators of comorbid pathology.
Materials and methods: 120 patients (51 males and 69 females), aged 45-69 years with average age being (58.2±5.7) years, were studied: 25 patients with treatment-compensated EAH, 1-2 degree, II stage (Group I); 25 patients with subcompensated DM2 (Group II) and 70 patients with treatment-compensated EAH, 1-2 degree, II stage and concomitant subcompensated DM2 (Group III). Control group consisted of 20 practically healthy volunteers - 8 (40.0%) males and 12 (60.0%) females, aged (54.7±4.9) years. Groups were randomized according to age, sex, BMI, duration of EAH and DM2.
Results and discussion: Asymptomatic hyperuricemia were observed in 36.0% of group І patients, in 24.0% of group II patients and in 46.7% of group ІІІ patients. Relevant correlations were found between uric acid level in the blood and such indicators as/for systolic blood pressure (SBP), glycated hemoglobin (HbA1C), dyslipidemia, inflammatory process, and kidney damage.
Conclusion: Asymptomatic hyperuricemia has a negative effect on the main indicators of comorbid pathology - in this case, EAH and concomitant DM2.
MOH Ukraine (2012) Adapted clinical guidelines, based on evidence “Diabetes mellitus type 2” Order No. 1118 dated 21.12.2012 Available: http://www.moz.gov.ua/docfiles/dod1118_1_2012_.pdf.
Tronko MD (2014) Reference key performance indicators in endocrinological service of Ukraine for 2013. Endocrinology 19(1):40.
American Diabetes Association (ADA) (2017) Standards of medical care in diabetes. Diabetes care 40(1):75-98.
MOH Ukraine (2012) Guidelines and clinical protocols of medical care “Arterial hypertension” Order No. 384 dated 24.05.2012. Page 107.
Trifiro G, Sultana J, Giorgianni F, Ingrasciotta Y, Buemi M, Muscianisi M, et al (2014), Chronic kidney disease requiring healthcare services: a new approach to evaluate epidemiology of renal disease. BioMed Research International DOI: http://dx.doi.org/10.1155/2014/268362.
Tashchuk VK, Vasek Obeid Al' Salama Muhamed (2016) Comorbidity, cardiovascular pathology and treatment of hyperuricemia - does allopurinol prevent its development? Bukovynsky medical bulletin 20(2): 209-212.
Vassalle C, Mazzone A, Sabatino L, Carpeggiani C (2016) Uric acid for cardiovascular risk: Dr. Jekyll or Mr. Hide? Diseases 4(1) DOI: 10.3390/diseases4010012.
Zhdan VM, Kitura OYe, Kitura YeM, Babanina MYu, Tkachenko MV (2015) Hyperuricemia and arterial hypertension in general medical practice. Family medicine 4: 48-50.
Yakymenko YL (2014) Features of arterial hypertension combined with hyperuricemia in men. Ukr. med. journal 1(99): 1-2. Available online:http://www.umj.com.ua/article/70737/osobennosti-arterialnoj-gipertenzii-pri-sochetanii-s-giperurikemiej-u-muzhchin.
Mishchenko LA (2016) Hyperuricemia and arterial hypertension – is there a connection? Ukrainian cardiology journal 3: 24-29.
El Ridi R, Tallima HJ (2017) Physiological functions and pathogenic potential of uric acid: a review. Adv. Res. 8(5):487-493. DOI:10.1016/j.jare.2017.03.003.
Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E (2013) Uric acid and chronic kidney disease: which is chasing which? Nephrology Dialysis Transplantation 28(9): 2221-2228. DOI: 10.1093/ndt/gft029.
Jalal DI, Chonchol M, Chen W, Targher G (2013) Uric acid as a target of therapy in CKD. American Journal of Kidney Diseases 61:134–146.
Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al (2015) Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. American Journal of Kidney Diseases 65:543–549.
Kimura K, Hosoya T, Uchida S, et al (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. American Journal of Kidney Diseases 72: 798-810.
Mallamaci CZF (2018) Uric acid in chronic kidney disease: the quest for causality continues. Nephrology Dialysis Transplantation 33(2): 193-195. DOI: 10.1093/ndt/gfx341.